Chinook Therapeutics Announces Upcoming Encore Presentations at ISN World Congress of Nephrology 2022
February 18, 2022 08:15 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2022 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces Appointment of Charlotte Jones-Burton, M.D., M.S. as Senior Vice President of Product Development and Strategy
January 24, 2022 08:15 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at Upcoming Investor Conferences
January 04, 2022 08:15 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Receives Orphan Drug Designation from European Commission for Atrasentan for Treatment of Primary IgA Nephropathy
December 14, 2021 08:15 ET
|
Chinook Therapeutics, Inc.
Enrollment ongoing in atrasentan pivotal phase 3 ALIGN study in IgAN and phase 2 AFFINITY study in proteinuric glomerular diseasesChinook expects to present data from the IgAN patient cohort of the...
Chinook Therapeutics Announces Formation of SanReno Therapeutics, a Joint Venture to Develop Kidney Disease Therapies in China
November 30, 2021 08:00 ET
|
Chinook Therapeutics, Inc.
50/50 joint venture with investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners ChinaExpands global reach and execution for Chinook’s atrasentan and BION-1301 programs...
Chinook Therapeutics to Present at Upcoming Investor Conferences
November 17, 2021 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces Closing of $183.5 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 15, 2021 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the closing of its upsized underwritten public offering of 9,538,572 shares of its common stock...
Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering
November 09, 2021 20:36 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its upsized underwritten public offering of 7,828,572 shares of its common stock...